| (Values in U.S. Thousands) | Jun, 2015 | Jun, 2014 | Jun, 2013 | Jun, 2012 | Jun, 2011 |
| Sales | 24,600 | 68,700 | 33,600 | 630 | 14,840 |
| Sales Growth | -64.19% | +104.46% | +5,233.33% | -95.75% | -57.61% |
| Net Income | -19,100 | -11,000 | -8,700 | -2,730 | -4,530 |
| Net Income Growth | -73.64% | -26.44% | -218.68% | +39.74% | -614.77% |
Biota Pharmaceutical (BOTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Biota Pharmaceuticals, Inc., formerly known as Nabi Biopharmaceuticals, is an anti-infective drug development company with focus in respiratory diseases, particularly influenza. Registered drugs of the Company includes: Relenza (T), a neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline; and, Inavir ( R ), an influenza antiviral, registered to Daiichi Sankyo. Biota Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.